早期外周型脊柱关节炎十年随访:CRESPA 试验的无药缓解
CRESPA 试验纳入症状持续时间≤12 周的早期外周型脊柱关节炎(pSpA)患者,随机接受戈利木单抗 50 mg 每 4 周或安慰剂治疗。10 年随访时 81.6%(40/49)患者处于临床缓解,30.6%(15/49)达到长期无药缓解;基线无银屑病患者更易达到无药缓解(OR 9.1,95%CI 1.8-50)。
要点
- 早期 pSpA 经戈利木单抗诱导缓解后,10 年时多数患者维持临床缓解。
- 约三分之一患者达到长期无药缓解,基线无银屑病者比例接近一半。
- 缓解与性别、年龄、HLA-B27、银屑病及初始治疗分配无关。
核心结论
- 早期 pSpA 的缓解诱导治疗可使多数患者获得持续临床缓解,三分之一达到无药缓解。
- 基线无银屑病的 pSpA 患者中近半数维持无药缓解,提示早期强化治疗可能实现长期疾病控制。
研究设计与样本
- CRESPA 研究为随机对照试验,患者符合 ASAS 外周型脊柱关节炎分类标准且症状持续时间≤12 周。
- 患者随机接受戈利木单抗 50 mg 每 4 周或安慰剂治疗,10 年后进行标准化评估。
- 原始 60 例患者中 49 例完成随访,平均随访 10.5(±0.87)年。
主要发现
- 81.6%(40/49)患者处于临床缓解,30.6%(15/49)达到长期无药缓解。
- 基线无银屑病患者达到无药缓解的比值比为 9.1(95%CI 1.8-50),非银屑病 pSpA 中 48.1%(13/27)维持无药缓解。
- 缓解与性别、年龄、HLA-B27 阳性、银屑病及初始治疗分配无关。
- 处于缓解的患者健康相关生活质量和躯体功能显著更优。
关键数值与推荐
- 临床缓解定义为无肿胀关节、附着点炎或指(趾)炎。
- 无药缓解定义为长期未用药情况下维持临床缓解。
临床怎么用
- 对早期 pSpA 患者可考虑积极诱导缓解,以争取长期临床缓解甚至无药缓解。
- 基线无银屑病的 pSpA 患者无药缓解可能性更高,可作为预后参考。
局限性
- 原文为描述性分析,样本量较小(49 例完成随访)。
- 原文未报告盲法、脱落原因及长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to provide a descriptive analysis of the 10-year follow-up data from the Clinical Remission in Peripheral Spondyloarthritis (CRESPA) study. Here, patients fulfilling the Assessment of Spondyloarthritis International Society peripheral spondyloarthritis (pSpA) classification criteria, with symptom duration ≤12 weeks, were randomized to golimumab 50 mg every four weeks or placebo. Our aims were to assess the proportion of patients in (drug-free) clinical remission and identify baseline predictors of achieving (drug-free) remission at 10-year follow-up. METHODS: All patients from the original CRESPA study were invited for a standardized evaluation 10 years after inclusion. Clinical remission was defined as the absence of swollen joints, enthesitis, or dactylitis. RESULTS: Of 60 original patients, 49 were evaluated after a mean (±SD) of 10.5 (±0.87) years. Of the patients, 81.6% (40 of 49) were in clinical remission, of whom 30.6% (15 of 49) achieved longstanding drug-free remission. Remission was not linked to baseline characteristics like sex, age, HLA-B27 positivity, psoriasis, or initial treatment allocation. Patients without psoriasis at baseline were significantly more likely to achieve drug-free remission (odds ratio 9.1, 95% confidence interval 1.8-50), with 48.1% patients with nonpsoriatic pSpA (13 of 27) remaining in drug-free remission. Health-related quality of life and physical function were significantly better in patients in remission. CONCLUSION: Remission induction with golimumab in patients with early pSpA enables achievement of sustained clinical remission in the majority of patients, with one-third of patients attaining drug-free remission. Strikingly, almost half of patients with nonpsoriatic pSpA remained in drug-free remission. These findings strongly suggest that early, intensive treatment has the potential to achieve long-term disease control, potentially leading to sustained drug-free remission in a subset of patients.
引用
- Damen C, De Craemer AS, Webers C, et al. Drug-Free Remission in Early Peripheral Spondyloarthritis, Including Psoriatic Arthritis: 10-Year Follow-Up From the CRESPA Trial. Arthritis Rheumatol. 2026. PMID: 42765471. doi:10.1002/art.70349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。